(ASPEX: Pittsburgh, Pennsylvania) -- Following the U.S. Food and Drug Administration’s recent decision to join European and Australian authorities in the inspection of overseas drug manufacturing facilities, the pharmaceutical industry is re-examining its approach to quality control. In response to this trend, ASPEX has announced the release of its Rx microanalysis system, the first all-in-one system designed for detecting and characterizing microscopic contaminants in pharmaceuticals.

Developed in conjunction with one of the world's leading pharmaceutical companies, the Rx represents the only integrated solution for microcontamination quality control on the production floor. Because counterfeit or contaminated drugs can result in allergic reactions or even death (as evidenced by the widely-publicized heparin epidemic), the Rx’s ability to identify harmful particles as small as 30 nanometers yields far-reaching effects for consumer safety. Complete with a full complement of FDA compliance features, these instruments have been successfully installed at a wide range of current good manufacturing practices (cGMP) facilities.

 …